Zydus’s weight-loss injection to reach India via Lupin partnership

Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide more accessible in India. This collaboration follows the upcoming expiry of Novo Nordisk's patent. Lupin will co-market Zydus's semaglutide injection under its own brand. This move aims to reach more patients across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/duKU36L
via IFTTT